trending Market Intelligence /marketintelligence/en/news-insights/trending/vo5ap1xeyybaaakdvopdpa2 content esgSubNav
In This List

Intra-Cellular initiates rolling submission of schizophrenia drug in US

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Intra-Cellular initiates rolling submission of schizophrenia drug in US

New York-based Intra-Cellular Therapies Inc. initiated the rolling submission of its schizophrenia drug lumateperone with the U.S. Food and Drug Administration.

Under a rolling submission, the company can submit completed sections of its new drug application rather than waiting until every section of the application is completed before the entire application can be reviewed.

The company plans to complete its new drug application submission in mid-2018.

The treatment was granted the fast-track designation by the regulator in 2017.